Treatment Switching in the VenUS IV trial Methods to manage treatment non-compliance in RCTs with time-to-event outcomes Caroline Fairhurst York Trials.

Slides:



Advertisements
Similar presentations
CQ Deng, PhD PPD Development Research Triangle Park, NC 27560
Advertisements

Appraisal of an RCT using a critical appraisal checklist
COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those.
Hypothesis Testing Goal: Make statement(s) regarding unknown population parameter values based on sample data Elements of a hypothesis test: Null hypothesis.
Survival Analysis-1 In Survival Analysis the outcome of interest is time to an event In Survival Analysis the outcome of interest is time to an event The.
Use of Placebos in Controlled Trials. Background The traditional ‘double-blind’ RCT uses a placebo to conceal allocation. There are a number of advantages.
Treatment Switching and Overall Survival in Oncology
1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.
Design & Interpretation of Randomized Trials: A Clinician’s Perspective Francis KL Chan Department of Medicine & Therapeutics CUHK.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
RELATIVE RISK ESTIMATION IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF METHODS FOR INDEPENDENT OBSERVATIONS Lisa N Yelland, Amy B Salter, Philip Ryan.
What size of trial do I need? Peter T. Donnan Professor of Epidemiology and Biostatistics Co-Director of TCTU Statistics for Health Research.
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Handling treatment changes in randomised trials with survival outcomes UK Stata Users' Group, September 2014 Ian White MRC Biostatistics Unit, Cambridge,
Research Techniques Made Simple: Pragmatic or Explanatory Trial? The BLISTER Study The Bullous Pemphigoid Steroids and Tetracyclines Study Hywel Williams.
Sample size and analytical issues for cluster trials David Torgerson Director, York Trials Unit
Common Problems in Writing Statistical Plan of Clinical Trial Protocol Liying XU CCTER CUHK.
Biostatistics in Research Practice Time to event data Martin Bland Professor of Health Statistics University of York
1 Equivalence and Bioequivalence: Frequentist and Bayesian views on sample size Mike Campbell ScHARR CHEBS FOCUS fortnight 1/04/03.
Clinical trials methodology group Simon Gates 9 February 2006.
Pragmatic Randomised Trials. Background Many clinical trials take place in artificial conditions that do not represent NORMAL clinical practice. Often.
BS704 Class 7 Hypothesis Testing Procedures
Adjusting overall survival for treatment switch
Pre-randomisation consent (Zelen’s method)
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Sample Size Annie Herbert Medical Statistician Research & Development Support Unit Salford Royal Hospitals NHS Foundation Trust
Sample Size Determination
Sample Size Determination Ziad Taib March 7, 2014.
Power and Sample Size Part II Elizabeth Garrett-Mayer, PhD Assistant Professor of Oncology & Biostatistics.
Professor of Epidemiology and Biostatistics
Choosing Statistical Procedures
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Sarah Struthers, MD March 19, 2015
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Addressing missing participant data in systematic reviews: Part I – Dichotomous outcomes Elie Akl, Shanil Ebrahim, Bradley Johnston, Pablo Alonso, Matthias.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Statistical approaches to analyse interval-censored data in a confirmatory trial Margareta Puu, AstraZeneca Mölndal 26 April 2006.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Julio A. Ramirez, MD, FACP Professor of Medicine Chief, Infectious Diseases Division, University of Louisville Chief, Infectious Diseases Section, Veterans.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Understanding real research 4. Randomised controlled trials.
Evidence-Based Medicine Presentation [Insert your name here] [Insert your designation here] [Insert your institutional affiliation here] Department of.
RCTs and instrumental variables Anna Vignoles University of Cambridge.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Allocated to IV arm (n=85) Allocated to HIA arm (n=86) Started allocated intervention (n=83) Did not receive allocated therapy (n=2) - Refusal (n=2) Started.
Understanding Study Design & Statistics Dr Malachy O. Columb FRCA, FFICM University Hospital of South Manchester NWRAG Workshop, Bolton, May 2015.
Study designs. Kate O’Donnell General Practice & Primary Care.
1 Centre for Sport and Exercise Science, Sheffield Hallam University, U. K. 2 York Trials Unit, Department of Health Sciences, University of York, U. K.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
1 Using dynamic path analysis to estimate direct and indirect effects of treatment and other fixed covariates in the presence of an internal time-dependent.
Compliance Original Study Design Randomised Surgical care Medical care.
Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.
Some survival basics Developments from the Kaplan-Meier method October
European Patients’ Academy on Therapeutic Innovation The Purpose and Fundamentals of Statistics in Clinical Trials.
بسم الله الرحمن الرحیم.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
Carolinas Medical Center, Charlotte, NC Website:
Adjusting effects for treatment switching in HTA
Francis KL Chan Department of Medicine & Therapeutics CUHK
Randomized Trials: A Brief Overview
Sample Size Estimation
Challenges of statistical analysis in surgical trials
Common Problems in Writing Statistical Plan of Clinical Trial Protocol
An activity-based journal club to help staff & students improve confidence at reading scientific papers Cornwall Health Library: Katy Oak Catriona Organ.
Intent-to-treat Analysis of Randomized Clinical Trials.
1Kantarjian HM et al. Lancet Oncol 2011;12:
Presentation transcript:

Treatment Switching in the VenUS IV trial Methods to manage treatment non-compliance in RCTs with time-to-event outcomes Caroline Fairhurst York Trials Unit

Context Two arm RCT Clinical setting Continuous treatment Time-to-event outcome (e.g., death, healing)

Dream or reality? Ideal All participants will remain in the trial throughout follow-up Will be concordant with their allocated treatment Will provide outcome data Reality Participants withdraw from the trial and are lost to follow-up Withdraw from treatment Deviate from their allocated trial treatment

Treatment switching

Problem? Switching to the alternative trial treatment makes randomised groups more similar Dilutes the treatment effect observed from a comparison of treatment groups as randomised ignoring deviations from allocated treatment (ITT) If you want to estimate the effect had fewer switches occurred, ITT analysis biased towards the null of no difference

VenUS IV trial Venous leg ulcers are wounds that form on gaiter region of the leg They are painful, malodorous and prone to infection Difficult to heal and 12 month recurrence rates are 18-28% VenUS I, II, III Four layer bandaging is current gold standard

VenUS IV trial Population: Patients aged over 18 with at least one venous leg ulcer and able to tolerate high compression to the leg Intervention: Two layer high compression hosiery Control: Four layer high compression bandaging Outcome: Time to healing of the largest ulcer

Treatment switching Randomised n=457 Hosiery n=230 Bandage n=224 HosieryBandage Non-trial treatment n=42 Non-trial treatment n=46 n=16

Treatment switching Increase in ulcer area Compression uncomfortable Ulcer deterioration

Simple methods - ITT Intention-to-treat ITT recommended (ICH E9) Compares individuals in the treatment groups to which they were randomised Estimates the effect of offering the two treatment policies to patients with whatever subsequent changes may occur “pragmatic effectiveness not biological efficacy” But what about effect of receiving experimental treatment?

Simple methods - PP Per-protocol 1. Excludes patients who switch Assumptions: Switchers have same prognosis as non-switchers so selection bias not introduced 2. Censor patients at time of switch Assumptions: Decision to switch not related to prognosis so censoring non-informative

Simple methods - TTV Treatment as a time-varying covariate Time-to-event model adjusted for time-dependent treatment covariate: 0, whilst receiving control treatment 1, whilst receiving experimental treatment Breaks randomisation balance and so subject to selection bias if switching related to prognosis trt=

Complex methods Time on control treatment Time on experimental treatment Acceleration factor

RPSFTM

Control patient Randomisation Death Control patient who switches Observed Death Time Counterfactual Death Counterfactual Observed Treatment patient

RPSFTM

Assumptions Randomisation based treatment effect estimator Rank preserving: if patient i fails before patient j on treatment A, then i would fail before j on treatment B Assumes the treatment effect is the same regardless of when patient starts to receive experimental treatment

Complex methods

IPE

AF or HR?

Application to VenUS IV MethodTreatment effect form Estimate95% CIP-value ITTHR0.99(0.79, 1.25)0.96 PP_EXCHR1.10(0.86, 1.41)0.43 PP_CENSHR1.23(0.98, 1.54)0.08 TTVHR1.20(0.95, 1.50)0.13 RPSFTM_log0.92(0.66, 1.28)0.63 RPSFTM_cox0.91(0.69, 1.21)0.53 IPE_exp IPE_wei0.88--

Simulation A simulation study suggested that the simple methods can significantly overestimate the true treatment effect, whilst the more complex methods of RPSFTM and IPE produce less biased results

Conclusion ITT analysis recommended as primary analysis Consider a method to estimate the true effect of efficacy as secondary analysis, but not PP Different methods can be used for continuous or categorical variables, e.g. CACE analysis

Acknowledgements York Trials Unit VenUS IV trial team Supervisor, Professor Mike Campbell (ScHARR, Sheffield)

References Ashby, R. L., et al. (2014). "Clinical and cost-effectiveness of compression hosiery versus compression bandages in treatment of venous leg ulcers (Venous leg Ulcer Study IV, VenUS IV): a randomised controlled trial." The Lancet 383(9920): Robins, J. and A. Tsiatis (1991). "Correcting for non-compliance in randomized trials using rank preserving structural failure time models." Communications in Statistics-Theory and Methods 20(8): White, I., et al. (1999). "Randomization-based methods for correcting for treatment changes: Examples from the Concorde trial." Statistics in Medicine 18(19): White, I., et al. (2002). "strbee: Randomization-based efficacy estimator." The Stata Journal 2(Number 2): Branson, M. and J. Whitehead (2002). "Estimating a treatment effect in survival studies in which patients switch treatment." Statistics in Medicine 21: